<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952275</url>
  </required_header>
  <id_info>
    <org_study_id>USZ-DER-AAN-019</org_study_id>
    <nct_id>NCT01952275</nct_id>
  </id_info>
  <brief_title>Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases</brief_title>
  <acronym>NEUTROGENE</acronym>
  <official_title>Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin
      Diseases. After collecting informed consent, all patients' clinical phenotype is graded at
      inclusion with a detailed case report form and a discovery cohort formed based on the
      certainty of diagnosis. The DNA of patients in the discovery cohort is analyzed by whole
      exome sequencing which identifies all protein-coding genetic variants. Subsequently,
      statistical burden tests are going to identify enrichment of rare coding genetic variants in
      patients affected by Neutrophil-Mediated Inflammatory Skin Diseases.

      The ultimate goal is to reveal the responsible gene(s) that may then be targets for clinical
      intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Timeframe:

        -  Collection of DNA for discovery cohort until 05/2016

        -  Data analysis until 12/2014 for pyoderma gangrenosum, until 12/2016 for other NMID

        -  Report and data presentation early 2015 for PG, 2017 for other NMID
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Enrichment of rare coding genetic variants</measure>
    <time_frame>baseline</time_frame>
    <description>Whole exome sequencing is going to detect rare coding genetic variants in cases of Neutrophil-Mediated Inflammatory Skin Diseases. Statistical burden tests are applied to test for excess of rare variants in cases versus available controls of matching ancestry.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue</condition>
  <condition>Pyoderma Gangrenosum</condition>
  <condition>Erosive Pustular Dermatosis of the Scalp</condition>
  <condition>Sweet's Syndrome</condition>
  <condition>Behcet's Disease</condition>
  <condition>Bowel-associated Dermatosis-arthritis Syndrome</condition>
  <condition>Pustular Psoriasis</condition>
  <condition>Acute Generalized Exanthematous Pustulosis</condition>
  <condition>Keratoderma Blenorrhagicum</condition>
  <condition>Sneddon-Wilkinson Disease</condition>
  <condition>IgA Pemphigus</condition>
  <condition>Amicrobial Pustulosis of the Folds</condition>
  <condition>Infantile Acropustulosis</condition>
  <condition>Transient Neonatal Pustulosis</condition>
  <condition>Neutrophilic Eccrine Hidradenitis</condition>
  <condition>Rheumatoid Neutrophilic Dermatitis</condition>
  <condition>Neutrophilic Urticaria</condition>
  <condition>Still's Disease</condition>
  <condition>Erythema Marginatum</condition>
  <condition>Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes</condition>
  <condition>Dermatitis Herpetiformis</condition>
  <condition>Linear IgA Bullous Dermatosis</condition>
  <condition>Bullous Systemic Lupus Erythematosus</condition>
  <condition>Inflammatory Epidermolysis Bullosa Aquisita</condition>
  <condition>Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis)</condition>
  <condition>Small Vessel Vasculitis Including Urticarial Vasculitis</condition>
  <condition>Erythema Elevatum Diutinum</condition>
  <condition>Medium Vessel Vasculitis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of biological samples</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva or Blood Serum Histology FFPE
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a history of Neutrophil-Mediated Inflammatory Dermatoses (NMID) of any
        subtype
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  History of NMID or active disease.

          -  Informed consent.

        Exclusion criteria:

        - No consent to either part of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Navarini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Dept. of Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Navarini, MD</last_name>
    <email>alexander.navarini@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich, Dept. of Dermatology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Erythema</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Pemphigus</mesh_term>
    <mesh_term>Pyoderma</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Pyoderma Gangrenosum</mesh_term>
    <mesh_term>Familial Mediterranean Fever</mesh_term>
    <mesh_term>Dermatitis Herpetiformis</mesh_term>
    <mesh_term>Skin Diseases, Vesiculobullous</mesh_term>
    <mesh_term>Linear IgA Bullous Dermatosis</mesh_term>
    <mesh_term>Acute Generalized Exanthematous Pustulosis</mesh_term>
    <mesh_term>Vasculitis, Leukocytoclastic, Cutaneous</mesh_term>
    <mesh_term>Epidermolysis Bullosa Acquisita</mesh_term>
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Sweet Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

